A Phase 1, Open-label, Multi-center, Dose-escalation Study to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of ISU304 in Previously Treated Hemophilia B Patients

Trial Profile

A Phase 1, Open-label, Multi-center, Dose-escalation Study to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of ISU304 in Previously Treated Hemophilia B Patients

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Sep 2017

At a glance

  • Drugs CB 2679d (Primary) ; CB 2679d (Primary) ; Nonacog alfa (Primary)
  • Indications Haemophilia B
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors ISU Abxis
  • Most Recent Events

    • 25 Sep 2017 According to a Catalyst Biosciences media release, dosing of the first subcutaneous cohort (n=3) of the trial has been completed.
    • 06 Sep 2017 Interim, top-line results of this open-label study are expected by the end of 2017 and complete trial results in early 2018, as reported in a Catalyst Biosciences
    • 06 Sep 2017 Interim results (n=3) from first Cohort of this trial published in the Catalyst Biosciences Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top